Relevant bibliographies by topics / Alternative cancer cures

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Alternative cancer cures'

Author: Grafiati
Published: 4 June 2021
Last updated: 6 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Alternative cancer cures.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Alternative cancer cures"

1

Farrugia, David, and Maurice L. Slevin. "Alternative cancer cures." Lancet Oncology 1, no. 4 (December 2000): 204–5. http://dx.doi.org/10.1016/s1470-2045(00)00147-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ernst, E. "Alternative cancer cures." British Journal of Cancer 85, no. 5 (August 2001): 781–82. http://dx.doi.org/10.1054/bjoc.2001.1989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vickers, A. "Alternative Cancer Cures: "Unproven" or "Disproven"?" CA: A Cancer Journal for Clinicians 54, no. 2 (March 1, 2004): 110–18. http://dx.doi.org/10.3322/canjclin.54.2.110.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ernst, E., and K. Schmidt. "‘Alternative’ cancer cures via the Internet?" British Journal of Cancer 87, no. 5 (August 2002): 479–80. http://dx.doi.org/10.1038/sj.bjc.6600513.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ernst, Edzard, Lorenzo Cohen, Judy Gerner, Walter Baile, Simon Schraub, John Diamond, and Evan Ross. "‘Alternative cancer cures’: looking for common ground." Lancet Oncology 1, no. 1 (September 2000): 54–59. http://dx.doi.org/10.1016/s1470-2045(00)00172-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nogueira, Luciana, José Renildo Cavalho, Luciane Costa Dalboni, Thayná Neves Cardoso, Fabiana Toshie Konno, Leoni Villano Bonamin, and Elizabeth Cristina Perez. "Phytolacca decandra 30 CH dilution as an anticancer agent in murine mammary adenocarcinoma model." International Journal of High Dilution Research - ISSN 1982-6206 15, no. 4 (August 18, 2021): 11. http://dx.doi.org/10.51910/ijhdr.v15i4.840.

Full text
Abstract:
Homeopathy is an effective and safe therapy that provides better quality of life and reduces the adverse effects of conventional therapy used in different diseases. However, there are few published studies showing effects of homeopathic medicines in cancer models. Considering the principle "like cures like" the Phytolocca decandra causes similar symptoms to those presented in cancer subjects. Therefore, the aim of this study was to evaluate the effects of homeopathic preparations of Phytolacca decandra in the development of murine mammary tumor. For this, 4T1 mammary adenocarcinoma cells were inoculated subcutaneously in the inguinal breast of female BALB/c mice. Then, mice were blind treated with water containing only vehicle (control) or vehicle with Phytolacca decandra dilutions (6CH, 12CH, 30CH or 200cH). Tumor growth was monitored in alternated days during 21 days after tumor cells inoculation. Then, mice were euthanized and tumor, spleen, and lungs were removed to histological analyses. Results showed that animals treated with 30CH when compared with other groups exhibited tumor growth delay and smaller tumor weight, less vascularization and smaller relative weight of the spleen and pulmonary metastases. Together, results obtained in this pilot study demonstrated that treatment with Phytolacca decandra 30CH dilution induces delayed of breast tumor growth suggesting that this dilution may be a promising alternative therapy in the treatment of breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

Maspes, Anna, Fabio Pizzetti, Arianna Rossetti, Pooyan Makvandi, Giovanni Sitia, and Filippo Rossi. "Advances in Bio-Based Polymers for Colorectal Cancer Treatment: Hydrogels and Nanoplatforms." Gels 7, no. 1 (January 11, 2021): 6. http://dx.doi.org/10.3390/gels7010006.

Full text
Abstract:
Adenocarcinoma of the colon is the most common malignant neoplasia of the gastrointestinal tract and is a major contributor to mortality worldwide. Invasiveness and metastatic behavior are typical of malignant tumors and, because of its portal drainage, the liver is the closest capillary bed available in this case, hence the common site of metastatic dissemination. Current therapies forecast total resection of primary tumor when possible and partial liver resection at advanced stages, along with systemic intravenous therapies consisting of chemotherapeutic agents such as 5-fluorouracil. These cures are definitely not exempt from drawbacks and heavy side effects. Biocompatible polymeric networks, both in colloids and bulk forms, able to absorb large quantities of water and load a variety of molecules-belong to the class of innovative drug delivery systems, thus suitable for the purpose and tunable on each patient can represent a promising alternative. Indeed, the implantation of polymeric scaffolds easy to synthesize can substitute chemotherapy and combination therapies scheduling, shortening side effects. Moreover, they do not require a surgical removal thanks to spontaneous degradation and guarantees an extended and regional cargo release, maintaining high drug concentrations. In this review, we focus our attention on the key role of polymeric networks as drug delivery systems potentially able to counteract this dramatic disease.
APA, Harvard, Vancouver, ISO, and other styles
8

Karim, Rubaba, Mst Marium Begum, Md Abdul Alim, Md Sahab Uddin, Md Tanvir Kabir, Ashfia Fatima Khan, Tanjina Islam, Shafiul Islam Khan, and Md Sohanur Rahman. "Effects of Alcoholic Extracts of Bangladeshi Mangrove Acanthus ilicifolius Linn. (Acanthaceae) Leaf and Stem on Atherogenic Model of Wistar Albino Rats." Evidence-Based Complementary and Alternative Medicine 2021 (May 30, 2021): 1–18. http://dx.doi.org/10.1155/2021/7539037.

Full text
Abstract:
Acanthus ilicifolius Linn. (Acanthaceae) is a popular mangrove ethnomedicinal plant that cures several ailments, including asthma, diabetes, cancer, and many others. Our experiment was aimed at evaluating the anti-atherogenic effect of A. ilicifolius (leaf and stem) on a high-fat diet-induced atherogenic rat model. Atherosclerosis was developed in 12 weeks. Treatment with the standard drug (3 mg/kg b.w./day, p.o. of Simvastatin), separate doses of methanolic and ethanolic extracts of A. ilicifolius leaf (250 and 500 mg/kg b.w./day, p.o.), and stem (200 and 400 mg/kg b.w./day, p.o.) was subsequently conducted for additional 15 days. The anti-atherogenic effect was evaluated by estimating the change in body weight, systolic blood pressure, and lipid profile. Histopathology of aorta, liver, and kidney of atherogenic models was done for further evaluation. The antioxidant effect of different extracts was performed via DPPH (2,2-diphenyl-1-picrylhydrazyl) assay using ascorbic acid as standard. The anticoagulant effect was determined after 15 days of treatment with the same doses of the plant extracts and the standard Warfarin (2 mg/kg b.w./day, p.o.). When compared with atherogenic control, treatment with A. ilicifolius significantly reduced ( p < 0.01) body weight, systolic blood pressure, and serum lipid levels while it elevated HDL (high-density lipoprotein) level in a dose-dependent manner. Moreover, bleeding and clotting time was significantly decreased ( p < 0.01) under the treatment of plant extracts. The histopathological data showed considerable improvement in tissue morphology after treatment. Our study evidenced that the alcoholic extracts of A. ilicifolius leaf and stem have anti-atherogenic properties and may be recommended as a potential herbal remedy for preventing cardiovascular diseases.
APA, Harvard, Vancouver, ISO, and other styles
9

Ablain, Julien, and Hugues de The. "Revisiting the differentiation paradigm in acute promyelocytic leukemia." Blood 117, no. 22 (June 2, 2011): 5795–802. http://dx.doi.org/10.1182/blood-2011-02-329367.

Full text
Abstract:
Abstract As the result of intense clinical and basic research, acute promyelocytic leukemia (APL) has progressively evolved from a deadly to a curable disease. Historically, efforts aimed at understanding the molecular bases for therapy response have repeatedly illuminated APL pathogenesis. The classic model attributes this therapeutic success to the transcriptional reactivation elicited by retinoic acid and the resulting overcoming of the differentiation block characteristic of APL blasts. However, in clinical practice, retinoic acid by itself only rarely yields prolonged remissions, even though it induces massive differentiation. In contrast, as a single agent, arsenic trioxide neither directly activates transcription nor triggers terminal differentiation ex vivo, but cures many patients. Here we review the evidence from recent ex vivo and in vivo studies that allow a reassessment of the role of differentiation in APL cure. We discuss alternative models in which PML-RARA degradation and the subsequent loss of APL cell self-renewal play central roles. Rather than therapy aimed at inducing differentiation, targeting cancer cell self-renewal may represent a more effective goal, achievable by a broader range of therapeutic agents.
APA, Harvard, Vancouver, ISO, and other styles
10

Klener Jr, Pavel, Tomas Etrych, and Pavel Klener. "Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era." Current Medicinal Chemistry 26, no. 6 (May 13, 2019): 1002–18. http://dx.doi.org/10.2174/0929867324666171006144725.

Full text
Abstract:
:Less than 70 years ago, the vast majority of hematologic malignancies were untreatable diseases with fatal prognoses. The development of modern chemotherapy agents, which had begun after the Second World War, was markedly accelerated by the discovery of the structure of DNA and its role in cancer biology and tumor cell division. The path travelled from the first temporary remissions observed in children with acute lymphoblastic leukemia treated with single-agent antimetabolites until the first cures achieved by multi-agent chemotherapy regimens was incredibly short. Despite great successes, however, conventional genotoxic cytostatics suffered from an inherently narrow therapeutic index and extensive toxicity, which in many instances limited their clinical utilization. In the last decade of the 20th century, increasing knowledge on the biology of certain malignancies resulted in the conception and development of first molecularly targeted agents designed to inhibit specific druggable molecules involved in the survival of cancer cells. Advances in technology and genetic engineering enabled the production of structurally complex anticancer macromolecules called biologicals, including therapeutic monoclonal antibodies, antibody-drug conjugates and antibody fragments. The development of drug delivery systems (DDSs), in which conventional drugs were attached to various types of carriers including nanoparticles, liposomes or biodegradable polymers, represented an alternative approach to the development of new anticancer agents. Despite the fact that the antitumor activity of drugs attached to DDSs was not fundamentally different, the improved pharmacokinetic profiles, decreased toxic side effects and significantly increased therapeutic indexes resulted in their enhanced antitumor efficacy compared to conventional (unbound) drugs.:Approval of the first immune checkpoint inhibitor for the treatment of cancer in 2011 initiated the era of cancer immunotherapy. Checkpoint inhibitors, bispecific T-cell engagers, adoptive T-cell approaches and cancer vaccines have joined the platform so far, represented mainly by recombinant cytokines, therapeutic monoclonal antibodies and immunomodulatory agents. In specific clinical indications, conventional drugs have already been supplanted by multi-agent, chemotherapy-free regimens comprising diverse immunotherapy and/or targeted agents. The very distinct mechanisms of the anticancer activity of new immunotherapy approaches not only call for novel response criteria, but might also change fundamental treatment paradigms of certain types of hematologic malignancies in the near future.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Alternative cancer cures"

1

Stasko, Carly. "A Pedagogy of Holistic Media Literacy: Reflections on Culture Jamming as Transformative Learning and Healing." Thesis, 2009. http://hdl.handle.net/1807/18109.

Full text
Abstract:
This qualitative study uses narrative inquiry (Connelly & Clandinin, 1988, 1990, 2001) and self-study to investigate ways to further understand and facilitate the integration of holistic philosophies of education with media literacy pedagogies. As founder and director of the Youth Media Literacy Project and a self-titled Imagitator (one who agitates imagination), I have spent over 10 years teaching media literacy in various high schools, universities, and community centres across North America. This study will focus on my own personal practical knowledge (Connelly & Clandinin, 1982) as a culture jammer, educator and cancer survivor to illustrate my original vision of a ‘holistic media literacy pedagogy’. This research reflects on the emergence and impact of holistic media literacy in my personal and professional life and also draws from relevant interdisciplinary literature to challenge and synthesize current insights and theories of media literacy, holistic education and culture jamming.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Alternative cancer cures"

1

Eidem, William Kelley. The doctor who cures cancer. New York: Sullivan & Foster Pub., 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Eidem, William Kelley. The man who cures cancer. Bethesda, MD: Be Well Books, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Doctors' Prescription for Healthy Living. Natural cancer cures: The definitive guide to using dietary supplements to fight and prevent cancer. Topanga, CA: Freedom Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

The healing of cancer: The cures, the cover-ups, and the solution now. Queensville, Ont., Canada: Marcus Books, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Matsen, Jonn. Mysterious causes & cures of illness: How to overcome every disease from constipation to cancer without any drugs or surgery. Canfield, Ohio: Fischer Pub. Corp, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ruzic, Neil P. Racing to a cure: A cancer victim refuses chemotherapy and finds tomorrow's cures in today's laboratories. Urbana: University of Illinois Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jones, T. Llew. Cancer curers, or quacks?: The story of a secret herbal remedy. Llandysul, Dyfed: Gomer, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Clark, Hulda Regehr. The cure for all cancers: Including over 100 case histories of persons cured. San Diego, CA: New Century Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Clark, Hulda Regehr. The cure for all cancers: Including over 100 case histories of persons cured : Plus two revolutionary electronic circuits, one to diagnose and monitor progress, the other to zap parasites and bacteria!. San Diego: New Century Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cancer Cures, Causes And Preventions. Nature Publishing Inc., 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Alternative cancer cures"

1

Ernst, Edzard. "Alternative Cancer Cures." In So-Called Alternative Medicine (SCAM) for Cancer, 59–125. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-74158-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ernst, Edzard. "Complementary and alternative medicine." In Oxford Textbook of Medicine, edited by John D. Firth, Christopher P. Conlon, and Timothy M. Cox, 201–6. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0028.

Full text
Abstract:
Complementary and alternative medicine can be defined as diagnosis, treatment, and/or prevention which complements mainstream medicine by contributing to a common whole, by satisfying a demand not met by orthodoxy, or by diversifying the conceptual frameworks of medicine. It is popular; hence doctors should know about it. The term covers a vast array of treatments and diagnostic techniques which have little in common except that they are not part of mainstream medicine. The most important modalities are acupuncture, phytotherapy, homeopathy, and spinal manipulation. In industrialized countries, typical users of complementary and alternative medicine are middle-aged, female, well-educated members of a high socioeconomic class. Indications range from chronic benign conditions where mainstream medicine does not offer a cure (e.g. back pain) to life-threatening diseases like cancer and AIDS.
APA, Harvard, Vancouver, ISO, and other styles
3

Thanh Tung, Bui. "Natural Product Compounds for Breast Cancer Treatment." In Handbook of Research on Advancements in Cancer Therapeutics, 606–26. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-6530-8.ch023.

Full text
Abstract:
Breast cancer is the primary cause of cancer death in women. Although current therapies have shown some promise against breast cancer, there is still no effective cure for the majority of patients in the advanced stages of breast cancer. Treatment with present synthetic drugs may lead to a number of adverse effects. Consequently, research into natural product compounds may provide an alternative pathway to determining effective against breast cancer. This chapter reviews molecular targets of breast cancer treatment as well as bioactive compounds sourced from bibliographic information such as Medline, Google Scholar, PubMed databases. The authors hope that this book chapter contributes significantly to previous and ongoing research and encourages further investigation into the potential of natural product compounds in breast cancer.
APA, Harvard, Vancouver, ISO, and other styles
4

Ogilvie, Greg. "COMPLEMENTARY AND ALTERNATIVE CANCER THERAPY: CURE OR QUACKERY?" In Veterinary Oncology Secrets, 93–99. Elsevier, 2001. http://dx.doi.org/10.1016/b978-1-56053-416-7.50022-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Iam-On, Natthakan, and Tossapon Boongoen. "Soft Subspace Clustering for Cancer Microarray Data Analysis." In Global Trends in Intelligent Computing Research and Development, 131–45. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4936-1.ch006.

Full text
Abstract:
A need has long been identified for a more effective methodology to understand, prevent, and cure cancer. Microarray technology provides a basis of achieving this goal, with cluster analysis of gene expression data leading to the discrimination of patients, identification of possible tumor subtypes, and individualized treatment. Recently, soft subspace clustering was introduced as an accurate alternative to conventional techniques. This practice has proven effective for high dimensional data, especially for microarray gene expressions. In this review, the basis of weighted dimensional space and different approaches to soft subspace clustering are described. Since most of the models are parameterized, the application of consensus clustering has been identified as a new research direction that is capable of turning the difficulty with parameter selection to an advantage of increasing diversity within an ensemble.
APA, Harvard, Vancouver, ISO, and other styles
6

Balduzzi, Adriana, Giovanna Lucchini, Jean-Hugues Dalle, and Rupert Handgretinger. "Allogeneic Stem-Cell Transplantation in Children and Adolescents with Malignancies." In Oxford Textbook of Cancer in Children, 52–63. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198797210.003.0007.

Full text
Abstract:
Allogeneic haematopoietic stem-cell transplantation (HSCT) is of benefit for children and adolescents affected with malignancies which are refractory to conventional chemotherapy. Since the first HSCT took place in 1957 and human leukocyte antigen (HLA) genetics were unravelled, thousands of patients have been virtually cured from their disease after undergoing HSCT. Eligibility criteria, donor selection, stem-cell source, conditioning regimen, graft-versus-host disease (GvHD) prophylaxis, and supportive therapy evolved over time and contributed to the reduction in transplant-related mortality. In this chapter, alternative donors are mentioned and the excursus which led to ongoing haploidentical HSCT approaches are detailed. Issues related to HSCT in acute lymphoblastic leukaemia (ALL) (the most frequent indication for HSCT in paediatrics), acute myeloid leukaemia, and solid tumours are discussed. The impact of minimal residual disease on HSCT outcome in ALL, strategies to exploit the graft-versus-tumour effect in solid tumours, and post-HSCT immunotherapy are highlighted.
APA, Harvard, Vancouver, ISO, and other styles
7

Ben-Arye, Eran, and Noah Samuels. "Integrative oncology in palliative medicine." In Oxford Textbook of Palliative Medicine, edited by Nathan I. Cherny, Marie T. Fallon, Stein Kaasa, Russell K. Portenoy, and David C. Currow, 849–60. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198821328.003.0081.

Full text
Abstract:
Patients with cancer frequently suffer from symptoms related to their disease or its treatment. Many seek out non-conventional medical treatments, often in an alternative setting and with an expectation that ‘natural’ remedies are both safe and effective in providing a ‘cure’ for their disease. While some non-conventional therapies can alleviate symptoms and improve quality of life, they may have adverse effects or herb–drug interactions, compromising treatment outcomes. Many cancer centres today have integrative oncology (IO) services which provide evidence-based guidance on the safe and effective use of complementary and integrative medicine (CIM) for symptom relief, improving quality of life and function. IO settings are headed by integrative physicians, with CIM treatments administered by a multidisciplinary team of medical, paramedical, and non-medical practitioners. CIM treatments are an effective adjunct to conventional supportive and palliative care, using a patient-centred approach to promote trust and better communication between patients and oncology healthcare professionals, including in palliative care. This chapter reviews the current state of IO as it is being provided in the conventional oncology setting, and suggests ways in which further integration can take place. An update on research-based evidence for CIM modalities relevant to palliative care will be presented, with an algorithm-based approach to the implementation of IO in conventional palliative oncology setting.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Alternative cancer cures"

1

Martin, David E. "PCLINES, A Parametric Lines Development Program for the Home Computer." In SNAME 18th Chesapeake Sailing Yacht Symposium. SNAME, 2007. http://dx.doi.org/10.5957/csys-2007-011.

Full text
Abstract:
An Excel© spreadsheet lines development program has been written for a home computer and is available to conference attendees. The program utilizes B-Spline parametric formulations for planar curve definition of the traditional hull lines: body, waterlines and buttocks. The user establishes the basic hull outline, in BSpline curves, by inputting bow and stern overhangs, freeboard at selected points, the draft of the canoe body at selected points, the beam on deck at selected points, and the maximum beam at the waterline. By judicious selections the user will see the resulting hull outline in profile and plan views, and can easily adjust these inputs to gain the desired hull outline. The user works with actual points on the hull rather than B-Spline vertices. The hull lines are then developed by the Excel program which establishes the hull form defined by the above outlines and satisfying inputs of the conventional hull form parameters: Center of Buoyancy, (Lcb) Center of Floatation, (Lcf) Prismatic Coefficient, (Cp), Maximum Section Coefficient, (Cm) and the Water-plane Coefficient, (Cwp). The lines development is accomplished in two steps. First, the user employs the Excel Solver to establish a waterline, and Sectional Area curve that satisfy the above parameters. The program accomplishes this by varying the draft at stations two and eight, which adjusts the shape of the center-plane curve without changing the draft, Tc. The solver ensures a “fair” waterline by minimizing the “bending” criterion of the waterline: that is, by minimizing the sum of the squares of d2y/du2 and d2x/du2. Here, y and x are defined by B-Spline formulations in the parameter “u”. The vertices of the B-Spline functions are varied by the Excel Solver to find the minimum bending criterion. Second, with the Section Area and waterline beam established for each station, the program establishes the shape of each station body curve which satisfies the section area, draft, freeboard and beams on deck and waterline. Fairness is again established by minimizing the “bending” criterion. Since there are no section areas for stations 10 and the transom, a scheme for constructing a transomgeometrically similar to station 9.5 is provided. Station 10 is established by fairing to the transom. The program can establish a round bottom hull in about a minute and a half after the input parameters are entered. It is essential however that the hull form parameters be selected judiciously. Clearly Lcb and Lcf must be compatible, and the hull outline must be reasonable in order to gain a fair hull. In this regard the user is provided with automatic input of six different hull shapes that provide good starting points for a design effort. Thus, in a matter of minutes the user can examine an alternate hull shape while keeping selected hull form parameters constant.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Alternative cancer cures' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography